139087-53-9 Usage
Uses
Used in Pharmaceutical Industry:
TYRPHOSTIN B48 is used as a research tool for studying the role of EGF-R in cell signaling pathways and its involvement in various diseases, particularly cancer. It helps researchers understand the mechanisms of EGF-R activation and its contribution to tumor growth and progression.
Used in Cancer Research:
TYRPHOSTIN B48 is used as an inhibitor of EGF-R for investigating its role in cancer cell growth and proliferation. By inhibiting EGF-R, it can cause cell cycle arrest at late G1 and S phase, which can be useful in understanding the underlying mechanisms of cancer development and identifying potential therapeutic targets.
Used in Drug Development:
TYRPHOSTIN B48 is used as a lead compound in the development of novel anti-cancer drugs targeting EGF-R. Its ability to inhibit EGF-R activity makes it a promising candidate for the development of targeted therapies for various types of cancer, including those driven by EGF-R overexpression or mutations.
Used in Cell Biology Research:
TYRPHOSTIN B48 is used as a cell growth inhibitor in cell biology research to study the effects of EGF-R inhibition on cell cycle progression, apoptosis, and other cellular processes. This helps researchers gain insights into the complex interplay between cell signaling pathways and the role of EGF-R in cellular homeostasis.
Check Digit Verification of cas no
The CAS Registry Mumber 139087-53-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,9,0,8 and 7 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 139087-53:
(8*1)+(7*3)+(6*9)+(5*0)+(4*8)+(3*7)+(2*5)+(1*3)=149
149 % 10 = 9
So 139087-53-9 is a valid CAS Registry Number.
139087-53-9Relevant academic research and scientific papers
Tyrphostins. 2. Heterocyclic and α-Substituted Benzylidenemalonitrile Tyrphostins as Potent Inhibitors of EGF Receptor and ErbB2/neu Tyrosine Kinases
Gazit, Aviv,Osherov, Nir,Posner, Israel,Yaish, Pnina,Poradosu, Enrique,et al.
, p. 1896 - 1907 (2007/10/02)
We have previously described a novel series of low molecular weight protein tyrosine kinase inhibitors which we named tyrphostins.The characteristic active pharmacophore of these compounds was the hydroxy-cis-benzylidenemalonitrile moiety.In this article we describe three novel groups of tyrphostins: (i) one group has the phenolic moiety of the cis-benzylidenemalononitrile replaced either with other substituted benzenes or with heteroaromatic rings, (ii) another is a series of conformationally constrained derivatives of hydroxy-cis-benzylidenemalononitriles in which the malononitrile moiety is fixed relative to the aromatic ring, and (iii) two groups of compounds in which the position trans to the benzenemalononitrile has been substituted by ketones and amides.Among the novel tyrphostins examined we found inhibitors which discriminate between the highly homologous EGF receptor kinase (HER1) and ErbB2/neu kinase (HER2).These findings may lead to selective tyrosine kinase blockers for the treatment of diseases in which ErbB2/neu is involved.
